MedTrace Logo

Measure of Plasma Tissue Factor to Predict a Venous Thromboembolism in Primitive Cancer of Lung

NCT02853188 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2019-08-15

No results posted yet for this study

Summary

The aim of the study is to evaluate if the plasma activity of the tissue factor at the time of the diagnosis of a lung cancer, before any treatment, or after the treatment of induction (surgery or two first cures of chemotherapy), can be a predictive factor of venous thromboembolism disease in the year which follows the diagnosis, independently of the other parameters.

Conditions

  • Cancer of Lung

Interventions

OTHER

venous thromboembolism

Sponsors & Collaborators

  • Hopital Foch

    lead OTHER

Principal Investigators

  • Marc VASSE, PhD · Hopitak Foch

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-04
Primary Completion
2018-12-20
Completion
2018-12-20

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02853188 on ClinicalTrials.gov